Clinical trial
Ontogeny of Measles Immunity in Infants
NCT00240916 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00240916 |
|---|---|
| Title | Ontogeny of Measles Immunity in Infants |
| Official title | Ontogeny of Vaccine-Induced Measles Immunity Child Participant-6 and 9 Months |
| Lead sponsor | Stanford University, Other |
| Status | Completed |
| Study type | Observational |
| Conditions | Measles |
| Intervention type | Biological |
| Interventions | Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous), MMR-II (Measles-Mumps-Rubella Virus Live Vaccine |
| Enrollment | 750 |
| Start date | Jul 1, 1993 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2013 |
| First posted | Oct 18, 2005 |
| Last update posted | Jun 9, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: